If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Mounjaro® (tirzepatide) be used with a GLP-1 receptor agonist?
There is no information on the use of tirzepatide with a GLP-1 receptor agonist.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide Use With GLP-1 Receptor Agonists
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucose-dependent insulinotropic polypeptide (GLP-1) receptor agonist. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors.1
There is no information on using tirzepatide with a GLP-1 receptor agonist because this combination has not been assessed in clinical studies.
Enclosed Prescribing Information
References
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Dungan K, DeSantis A. Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. UpToDate. Updated December 4, 2024. Accessed April 29, 2025. https://www.uptodate.com/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus
3American Diabetes Association. Standards of medical care in diabetes—2025. Diabetes Care. 2025;48(suppl 1):S1-S352. https://diabetesjournals.org/care/issue/48/Supplement_1
Date of Last Review: February 18, 2025